SCHEMBL3099359

SCHEMBL3099359

Cc1ccc(F)c(C(C)Oc2ccc(N)cc2)c1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD4 Q15561 1/20 0.34
TDP1 Q9NUW8 6/20 0.33
ALDH1A1 P00352 5/20 0.33
MAPK1 P28482 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
INPPL1 O15357 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 2/20 0.32
MET P08581 4/20 0.32
SRC P12931 2/20 0.32
KDR P35968 2/20 0.32
KIT P10721 1/20 0.32
FGFR2 P21802 1/20 0.32
AXL P30530 1/20 0.32
FLT3 P36888 1/20 0.32
MST1R Q04912 1/20 0.32
TSHR P16473 2/20 0.31
MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109433 0.89 TDP1 (0.36) TEAD4TDP1ALDH1A1MAPK1POLB
SCHEMBL3101643 0.85 MET (0.40) INPPL1SMN1; SMN2LMNAMETSRC
SCHEMBL3099533 0.84 INPPL1 (0.43) INPPL1METSRCKDRKIT
SCHEMBL3104424 0.79 HSPB1 (0.42) TDP1ALDH1A1MAPK1MAPTSMN1; SMN2
SCHEMBL3104697 0.77 MET (0.47) INPPL1METSRCKDRKIT
SCHEMBL3098304 0.75 CYP3A4 (0.50) ALDH1A1MAPK1MAPTSMN1; SMN2LMNA
SCHEMBL3093360 0.74 MET (0.56) INPPL1METSRCKDRKIT
SCHEMBL9945905 0.69 ACHE (0.33) LMNA
SCHEMBL23788293 0.68 ACHE (0.32)
SCHEMBL3102794 0.67 TDP1 (0.38) TEAD4TDP1ALDH1A1MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed
EP-2205568-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Sanofi-Aventis (FR) 2010-07-14 EP disclosed
WO-2009087305-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 TEAD4 4107/4885TDP1 4513/4885ALDH1A1 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.